Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
CMND
#5225
Clearmind Medicine Inc. Common Shares
1.1
3
-0.88%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-0.88%
Monatliche Änderung
-56.70%
6 month change
+10.78%
Jahresänderung
-8.13%
Vorheriger Schlusskurs
1.1
4
Open
1.1
3
Bid
Ask
Low
1.1
3
High
1.1
3
Volumen
2
Märkte
Aktien
Gesundheitswesen
CMND
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
1 099.81
15.18 K
106.63 K
158.08 K
—
Valuation ratios
Enterprise value
—
—
-6.43 M
-3.8 M
—
Price to earnings ratio
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
Price to book ratio
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
—
-1.45
-0.72
-0.63
—
Return on equity %
—
-8.77
-1.69
-3.23
—
Return on invested capital %
—
—
—
—
—
Gross margin %
—
100
—
—
—
Operating margin %
—
-456
—
—
—
EBITDA margin %
—
—
—
—
—
Net margin %
—
-52.07 K
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
—
136.56
1.72
1.22
—
Inventory turnover
—
—
—
—
—
Asset turnover
—
0
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
Working capital per share
—
—
—
—
—
Book value per share
—
—
—
—
—
Nachrichten
Clearmind Medicine: Aktie fällt trotz positiver Sicherheitsdaten aus klinischer Studie
Clearmind Medicine stock falls after Phase I/IIa trial safety update
Clearmind meldet positive Sicherheitsdaten in Studie zu Medikament gegen Alkoholkonsumstörung
Clearmind meldet positive Sicherheitsdaten für Medikamentenkandidaten gegen Alkoholkonsumstörung
Clearmind reports positive safety results in AUD drug trial
Clearmind reports positive safety data from AUD treatment trial
Clearmind-Aktie legt nach Deal für nasale Wirkstoffverabreichung deutlich zu
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal
Clearmind und Polyrizon kooperieren bei nasaler MEAI-Formulierung
Clearmind partners with Polyrizon to develop intranasal MEAI formulation
Polyrizon entwickelt nasale Formulierung für Clearminds Wirkstoffkandidaten MEAI
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug